Despite the growing prevalence of NASH, there are currently no approved treatments for the disease beyond liver transplant. The constellation of risk factors for NASH has generated a multitude of targets and there is an obvious need to bring promising treatments through clinical trials and to patients quickly.
Non-Invasive Serum Lipidomics to Identify NASH in T2D Patients
Created: January 15, 2025
